MedPacto Obtains European Patent for Pharmaceutical Composition for Cancer Prevention or Treatment
[Asia Economy Reporter Oh Ju-yeon] MedPacto announced on the 29th that it has obtained a European patent related to a pharmaceutical composition for cancer prevention or treatment and a method using the same. The company stated, "We are developing Vactosertib, which targets TGF-β that regulates the tumor microenvironment," and explained that "the patent concerns the composition and use for cancer prevention and treatment through the combined administration of our Vactosertib, which selectively inhibits TGF-β signaling, and immuno-oncology drugs."
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
They added, "Even if the exclusive license for Vactosertib expires in the future and generic versions of Vactosertib are launched, the rights related to combination therapy with immuno-oncology drugs will be protected by MedPacto's patent, effectively extending the period of MedPacto's rights protection."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
